Cancer cells may exploit “regulatory” pathways, such as checkpoint pathways, to hide from the immune system and shield the tumor from immune attack. OPDIVO® and YERVOY® are immune checkpoint inhibitors that target separate, distinct and complementary checkpoint pathways (PD-1 and CTLA-4).1 which increases your body’s immune response. The drugs activate immune cells—unleashing them, in effect—so that they can invade tumors and attack melanoma cells.
Ipilimumab blocks a checkpoint molecule called CTLA-4. CTLA-4 regulates the growth and activity of T cells, a type of white blood cell that attacks other cells in the body that look foreign, including some cancer cells. By blocking CTLA-4, ipilimumab activates your immune system against melanoma by allowing T cells to multiply and increase your body’s immune response.
Nivolumab blocks a different checkpoint molecule called PD-1, which helps protect tumor cells from being attacked by your immune system. Nivolumab removes the PD-1 “shield” to allow your immune system to find and attack melanoma cells.
reference: https://www.bmscanada.ca/en/news/release/first-ever-combination-of-two-immuno-oncology-agents-for-metastatic-melanoma-approved-by-health-cana , http://www.curemelanoma.org/about-melanoma/melanoma-treatment/combination-therapy-for-melanoma/nivolumab-opdivo-ipilimumab-yervoy/
Nivolumab (Opdivo) + Ipilimumab (Yervoy)
for treatment-naïve adult patients with advanced (unresectable or metastatic) melanoma, regardless of BRAF status. Currently under review with pCODR (Dec. 14, 2016) with a target review date of April 20, 2017. Has received NOC (Notice of Compliance with Health Canada) so is available for out of pocket purchase with a treating physician’s prescription or potentially through private insurance. Please check with your private insurance company regarding the terms of your plan’s coverage.
Nivolumab (Opdivo) + Ipilimumab (Yervoy) in combo for Metastatic Melanoma
Information from www.pcodr.ca
Funding Request: In combination, for treatment-naïve adult patients with advanced (unresectable or metastatic) melanoma, regardless of BRAF status
Review Status: Under Review
Dr. Marcus Butler
Expanding Horizons in Melanoma Treatment
Dr. Marcus Butler cares for patients with melanoma and gynecologic malignancies and is the Clinical Head of the Immune Monitoring Team at Princess Margaret Cancer Centre.
His work focuses on the development of immunotherapy trials, which include studies, alone and in combination, of immune checkpoint blocking antibodies, immunomodulators, and adoptive cell transfer.
Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma
Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.